Pöördumine

Grant Agreement number: 101129187 — EST-2-MyHealth — EU4H-2022-DGA-MS-IBA2

FINANCIAL STATEMENT FOR “TERVISE JA HEAOLU INFOSÜSTEEMIDE KESKUS” FOR REPORTING PERIOD 1

Eligible1 costs (per budget category) EU contribution Revenues

Direct costs Indirect costs EU contribution to eligible costs

A. Personnel costs B.

Subcontracting costs

C. Purchase costs D. Other costs

categories E. Indirect

costs2

Total costs Funding rate %3

Maximum EU contribution4

Requested EU contribution

Total requested EU contribution

Income generated

by the action

C.1 Travel and subsistenceA.1 Employees (or equivalent) A.2 Natural persons under direct contract A.3 Seconded persons

A.4 SME owners and natural person beneficiaries

B. Subcontracting

Travel Accommodation Subsistence

C.2 Equipment C.3 Other goods, works and services

D.1 Financial support to third parties

E. Indirect costs

Forms of funding

Actual costs Unit costs5 Actual costs Unit5 or

actual costs Unit5 or

actual costs Unit5 or

actual costs Actual costs Actual costs Actual costs

Flat- rate costs6

a1 a3 b c1a c1b c1c c2 c3 d1

e=flat-rate * (a1 + a3 + b + c1a + c1 b + c1c + c 2 + c3 + d1)

f=a1 + a3 + b + c1a + c1 b + c1c + c2 + c3 + d1 + e

U g=U * f h m n

TEHIK 65124.37 288632.73 0.00 0.00 0.00 0.00 0.00 0.00 24763.00 378520.10 80% 302816.08 302816.08 302816.08

The beneficiary/affiliated entity hereby confirms that: The information provided is complete, reliable and true. The costs and contributions declared are eligible (see Article 6). The costs and contributions can be substantiated by adequate records and supporting documentation that will be produced upon request or in the context of checks, reviews, audits and investigations (see Articles 19, 20 and 25). For the last reporting period: that all the revenues have been declared (see Article 22).

Please declare all eligible costs and contribution, even if they exceed the amounts indicated in the estimated budget (see Annex 2). Only amounts that were declared in your individual financial statements can be taken into account lateron, in order to replace costs/contributions that are found to be ineligible.

(1) See Article 6 for the eligibility conditions. All amounts must be expressed in EUR (see Article 21 for the conversion rules). (2) If you have also received an EU operating grant during this reporting period, you cannot claim indirect costs - unless you can demonstrate that the operating does not cover any costs of the action. This requires specific accounting tools. Please contact us immediately via the EU funding & Tenders Portal for details. (3) See Data Sheet for the funding rate(s). (4) This is the theoretical amount of EU contribution to costs that the system calculates automatically (by multiplying the reimbursement rates by the costs declared). The amount you request (in the ‘Requested EU contribution’) may be less. (5) See Annex 2a ‘Additional information on the estimated budget’ for the details (unit, cost per unit). (6) See Data Sheet for the flat-rate.

[--TGSMark#signature-895885405_40_395--]

1

Commission européenne/Europese Commissie, 1049 Bruxelles/Brussel, BELGIQUE/BELGIË - Tel. +32 22991111

This electronic receipt is a digitally signed version of the document submitted by your

organisation. Both the content of the document and a set of metadata have been digitally

sealed.

This digital signature mechanism, using a public-private key pair mechanism, uniquely

binds this eReceipt to the modules of the Funding & Tenders Portal of the European

Commission, to the transaction for which it was generated and ensures its full integrity.

Therefore a complete digitally signed trail of the transaction is available both for your

organisation and for the issuer of the eReceipt.

Any attempt to modify the content will lead to a break of the integrity of the electronic

signature, which can be verified at any time by clicking on the eReceipt validation

symbol.

More info about eReceipts can be found in the FAQ page of the Funding & Tenders

Portal.

(https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/support/faq)

2. List of Participants

PARTICIPANTS

Latest Legal Data Beneficiaries screens — Overview of the Consortium changes.

Number Role Short name Legal name Country PIC Entry date Exit date

1 COO MSAE SOTSIAALMINISTEERIUM Estonia 998429731

1.1 AE TEHIK TERVISE JA HEAOLU

INFOSÜSTEEMIDE KESKUS Estonia 895885405

1

1. PROJECT SUMMARY

Context and overall objectives

The objective of this project will be to ensure stable routine operations and necessary further development of the already operational NCPeH. Currently, the services deployed at the NCPeH are Patient Summary (in routine operations since August 2022) and ePrescriptions (in routine operations since January 2019).

Under the proposed action, the NCPeH will: - Ensure stable operations of the deployed MyHealth@EU services, more especially the Patient Summary service by bringing it to a new platform, which will enable a more reliable service and create better opportunities for any updates in the future. Estonia is currently in progress of major update to national Health Information System, which means that old national e-health services are being moved to a new platform as microservices. Under this objective, the Patient Summary service will also be brought to the new platform as a microservice which, in addition to being a more reliable service, will also allow to make continuous upgrades easier. - Improve the national allergy related data exchange standards to ensure allergy data for Patient Summary, which is currently incomplete. New national FHIR based standards will be created according to dataset, which will be agreed on between different national stakeholders. This will enable all Estonian health care providers to implement the new standards and start providing allergy related information to the National Health Information System (ENHIS). As Patient Summary is automatically composed of the data in ENHIS, it will also enable the necessary information in the Patient Summary service. The allergies and intolerances data section is considered part of the basic sections meaning that it must be present in a Patient Summary document. The missing data in this section for an Estonian Patient Summary is currently evaluated as finding and is in need for improvement. - Implement upgrades to the new versions of MyHealth@EU artefacts adopted yearly by the eHMSEG and participate in yearly formal and upgrade test events. - Translation of the Orphanet rare disease nomenclature (ORPHAcode) as a new value set, which has been added to the MyHealth@EU Master Valueset Catalogue. This would allow to display the information coming from other NCPeH in Estonian to Estonian health care professionals. The translation will be done in collaboration with Estonian rare diseases expert centre. The value set is currently planned to be translated in possible amount as, according to rare disease experts, not all codes can be translated/are reasonable to be translated.

Out of scope for this proposed action, but perhaps an effect of it is that the translation of ORPHAcode nomenclature would create an opportunity to move forward with the implementation of using the codes in national health data exchange in the future, which would allow for this information to be added to Patient Summary as well.

Work performed and main achievements

During the project's duration Estonia has ensured the stable operations of cross-border ePrescription and Patient Summary services. Developments for bringing the Patient Summary service to the new microservice platform have finished and the procurement contract has ended. However there are still

1

some development tasks that need to be done before this solution can be deployed live. Developments have been tested in our test environment and work will continue.

During autumn 2024 Estonia upgraded all cross-border systems to a new version (Wave 7) in live environment with other Member States and has continued to provide all four services to public and healthcare professionals. Estonia also took part in the MyHealth@EU Wave 8 Spring Test Session with all live services successfully and will finish all follow-up activities in order to successfully upgrade the services to Wave 8 in production during autumn 2025.

The work has started to improve national allergy standards. Analysis has been done and the validation with allergy and healthcare experts is currently ongoing to finalize the analysis and start developments.

Estonia has been in contact with Estonian rare diseases experts in order to start the ORPHA codes translating process. The administrative part with the International Orpha Coordinating Team has been agreed upon and TEHIK will organize a procurement soon.

Results and impacts

Patient Summary service has been brought to a micro service platform in test environment, as there are still more developments needed then there haven't been an impact in production environment yet. However it's expected to make future updates easier and make the service more reliable overall as Estonia keeps working towards creating a new generation health information system in order to guarantee sustainable support of the health care sector.

Estonia has upgraded its ePrescription and Patient Summary services according to the MyHealth@EU standards. New services have been opened with other joining Member States, such as Latvia and Lithuania, and thanks to this, the usage of these services continues to grow among citizens.

2

LIST OF MILESTONES

Milestones

Continuous Reporting (Milestones screen) — Update the status (and add new due date for late milestones, together with an explanation for the delay). In the Comments, please indicate if the milestone was achieved as planned or not.

MS No

Milestone Name Work Package

No

Lead Beneficiary Means of Verification Due Date

New Due Date (if delay)

Delivery Date

(actual)

Achieved Comments

1 Kick-off meeting – fixed date and agenda

WP1 TEHIK Description - Definition of the date and agenda of a meeting aimed at launching the project. Means of Verification - Date and agenda of the kick-off meeting fixed

30/11/2023 13/11/2023 Yes

2 Governance Participation

WP1 TEHIK Description - Governance participation, including the activities undergone at European level concerning the governance of service maintenance Means of Verification - Deliverable - Project Guide

30/9/2026 No

3 Communication and dissemination strategy

WP2 TEHIK Description: Communication strategy is compiled and its execution with reports, includes project content management system. Means of verification: Deliverable

31/1/2024 31/1/2024 Yes

1

Milestones

Continuous Reporting (Milestones screen) — Update the status (and add new due date for late milestones, together with an explanation for the delay). In the Comments, please indicate if the milestone was achieved as planned or not.

MS No

Milestone Name Work Package

No

Lead Beneficiary Means of Verification Due Date

New Due Date (if delay)

Delivery Date

(actual)

Achieved Comments

- Communication and dissemination strategy plan

4 Planning of MS Service Dissemination, Education and Training

WP2 TEHIK Description: Service dissemination, education and training schedule with activities, milestones and tasks. It provides a prospective vision on the tasks to be made in order to create awareness and prepare users towards the use of services. Means of verification: Deliverable - MS Service Dissemination, Education and Training Plan

28/2/2025 28/2/2025 Yes

5 Reporting of MS Service Dissemination, Education and Training Monitoring (Midterm)

WP2 TEHIK Description: Mid-term progress report on the education and training activity, containing MS Service Dissemination, Education and Training Monitoring. Means of verification: Deliverable - MS Service Dissemination,

31/1/2026 No

2

Milestones

Continuous Reporting (Milestones screen) — Update the status (and add new due date for late milestones, together with an explanation for the delay). In the Comments, please indicate if the milestone was achieved as planned or not.

MS No

Milestone Name Work Package

No

Lead Beneficiary Means of Verification Due Date

New Due Date (if delay)

Delivery Date

(actual)

Achieved Comments

Education and Training Monitoring Report (Midterm)

6 Reporting of MS Service Dissemination, Education and Training Monitoring (Final))

WP2 TEHIK Description: Final progress reporting on the education and training activity, containing MS Service Dissemination, Education and Training Monitoring would be included in the overall evaluation report foreseen under WP1. Means of verification: Deliverable - MS Service Dissemination, Education and Training Monitoring Report (Final)

31/10/2026 No

7 Draft evaluation and sustainability plan available

WP3 MSAE Description: The evaluation and sustainability plan draft with indicators for the project and each WP will be available for the consortium, EC and public Means of verificaiton: Draft has been circulated

31/1/2024 21/1/2024 Yes

3

Milestones

Continuous Reporting (Milestones screen) — Update the status (and add new due date for late milestones, together with an explanation for the delay). In the Comments, please indicate if the milestone was achieved as planned or not.

MS No

Milestone Name Work Package

No

Lead Beneficiary Means of Verification Due Date

New Due Date (if delay)

Delivery Date

(actual)

Achieved Comments

for comments and amending, resulting in Evaluation and sustainability plan

8 Draft mid-term evaluation and sustainability report is available

WP3 MSAE Description: The evaluation and sustainability report draft with assessment of the project and each WP will be available for the consortium, EC and public Means of verification: Draft has been circulated for comments and amending, resulting in Mid-term evaluation and sustainability report

30/4/2025 3/6/2025 Yes

9 Draft final evaluation and sustainability report available

WP3 TEHIK Description: The evaluation and sustainability report draft with the final assessment of the project and each WP will be available for the consortium, EC and public Means of verification: Draft has been circulated for comments and

31/8/2026 No

4

Milestones

Continuous Reporting (Milestones screen) — Update the status (and add new due date for late milestones, together with an explanation for the delay). In the Comments, please indicate if the milestone was achieved as planned or not.

MS No

Milestone Name Work Package

No

Lead Beneficiary Means of Verification Due Date

New Due Date (if delay)

Delivery Date

(actual)

Achieved Comments

amending, resulting in Final evaluation and sustainability report

10 Decision on continuation of routine operations M12

WP4 TEHIK Description: Annual decision taken by eHMSEG, based on the Outcome Summary report provided by the Solution Provider Means of verification: Deliverable eHMSEG decision M12

31/10/2024 31/10/2024 Yes

11 Decision on continuation of routine operations M24

WP4 TEHIK Description: Annual decision taken by eHMSEG, based on the Outcome Summary report provided by the Solution Provider Means of verification: Deliverable eHMSEG decision M24

31/10/2025 No

12 Reporting on service improvements

WP4 TEHIK Description: Reporting will include a description of the performed improvements affecting data availability and other service improvements. Means of

30/9/2026 No

5

Milestones

Continuous Reporting (Milestones screen) — Update the status (and add new due date for late milestones, together with an explanation for the delay). In the Comments, please indicate if the milestone was achieved as planned or not.

MS No

Milestone Name Work Package

No

Lead Beneficiary Means of Verification Due Date

New Due Date (if delay)

Delivery Date

(actual)

Achieved Comments

verification: Deliverable Service improvement report

13 Translation of the Orphanet rare disease nomenclature

WP4 TEHIK Description: Translation of the Orphanet rare disease nomenclature (ORPHAcode) as a new value set, which has been added to the MyHealth@EU Master Valueset Catalogue. Means of verification: Deliverable Service improvement report

30/9/2026 No

14 Upgrades implemented to the new versions of MyHealth@EU artefacts adopted yearly

WP4 TEHIK Description: Implement upgrades to the new versions of MyHealth@EU artefacts adopted yearly by the eHMSEG and participate in yearly formal and upgrade test events. Means of verification: deliverable Service improvement report

30/9/2026 No

15 Patient Summary service platform updates

WP4 TEHIK Description: Bringing Patient Summary service by to a new

30/9/2026 No

6

Milestones

Continuous Reporting (Milestones screen) — Update the status (and add new due date for late milestones, together with an explanation for the delay). In the Comments, please indicate if the milestone was achieved as planned or not.

MS No

Milestone Name Work Package

No

Lead Beneficiary Means of Verification Due Date

New Due Date (if delay)

Delivery Date

(actual)

Achieved Comments

platform, which will enable a more reliable service and create better opportunities for any updates in the future. Means of verification: Deliverable Service improvement report

16 Planning of service operation and maintenance

WP4 TEHIK Description: Operation and maintenance plan will include current needs and foreseeable expenditures related to daily operations, provision of customer support, software updates, hardware costs and costs for staff involved in the NCPeH operations. It will also include a description of the planned data quality improvements and other service improvements. Means of verification: Deliverable Service operation and maintenance plan

30/11/2023 4/12/2023 Yes

17 Reporting on service WP4 TEHIK Description: Reporting 30/9/2026 No

7

Milestones

Continuous Reporting (Milestones screen) — Update the status (and add new due date for late milestones, together with an explanation for the delay). In the Comments, please indicate if the milestone was achieved as planned or not.

MS No

Milestone Name Work Package

No

Lead Beneficiary Means of Verification Due Date

New Due Date (if delay)

Delivery Date

(actual)

Achieved Comments

operation and maintenance

will include effective expenditure covering daily operations, provision of customer support, software updates, hardware costs and costs for staff involved in the NCPeH operations. Means of verification: Deliverable Service operation and maintenance report

18 Project webpage update WP2 TEHIK Description: TEHIK website's relevant webpage is being updated during the project. Means of verification: Project webpage has been updated according to the Communication and dissemination strategy plan

31/10/2026 No

19 Report on specific action-level indicators

WP3 TEHIK Description: During the project KPIs are being monitored and reported as MyHealth@EU Monitoring Framework requires Means of

31/10/2026 No

8

Milestones

Continuous Reporting (Milestones screen) — Update the status (and add new due date for late milestones, together with an explanation for the delay). In the Comments, please indicate if the milestone was achieved as planned or not.

MS No

Milestone Name Work Package

No

Lead Beneficiary Means of Verification Due Date

New Due Date (if delay)

Delivery Date

(actual)

Achieved Comments

verification: report is made on the latest version of the KPIs as defined in the MyHealth@EU Monitoring Framework

9

Critical implementation risks and mitigation actions

Foreseen Risks

Foreseen risks The table shows the risks already listed in Annex 1 of the Grant Agreement (read-only).

Risk No Description Work Package No(s) Proposed Mitigation Measures

1 Progress starting too late and the project

resulting in poor delivery and project outcome (Likelihood: low, Impact: high)

WP1

Previous work has been done during the preparation of the Project. General management procedures have

been designed to detect any deviation from the initial plan and an experienced and robust management team will

lead the project. The kick-off meeting has been carefully designed to coherently launch all the simultaneous activities.

2 Deliverables or official notifications to HADEA submitted late (Likelihood: low, Impact: low)

WP1

The coordinator will keep abreast of the ongoing work, promote mutual sharing of updates within the consortium

and provide guidance to the consortium members in order to avoid delays. Responsibilities and procedures

will be clearly defined and implemented by partners under the coordinator’s, WP leaders’, task leaders’

supervision. The coordinator will also check the status of any deliverable to be sent to HaDEA 15 days before the deadline. Any delay will be communicated and justified beforehand, indicating the actual date of submission.

3 Financial deviations/ Budget issues that

do not allow for activities to be carried out (Likelihood: medium, Impact: medium)

WP1

The budget has been carefully designed, discussed and agreed with all partners. A financial manager will lead the evaluation and monitoring of the use of resources and its justification by all partners.

4 WP members do not deliver inputs to other WPs in time (Likelihood: high, Impact: low)

WP3,WP4,WP2,WP1

Coordination and constant monitoring carried out by WP1 will help prevent this issue. Attention will also be paid to building a strong relationship and trust among project

members. This can be reached, for example, by means of face-to-face meetings that will take place during the project.

5 Holidays, personal issues, COVID-19 pandemic

or any other health issues that cause some WP3,WP4,WP2,WP1

WP members make sure that they have a person in their team who can cover, at least partly, their participation

1

Foreseen risks The table shows the risks already listed in Annex 1 of the Grant Agreement (read-only).

Risk No Description Work Package No(s) Proposed Mitigation Measures

WP members to be missing for a certain period of time (Likelihood: low, Impact: low)

in the project. WP leaders and task leaders create back-up contact lists for having replacements in place.

6

Reports and deliverables do not meet required standards of written English

and/or presentation, data visualization, clarity (Likelihood: low, Impact: low)

WP3,WP4,WP2,WP1

Presence of an independent quality reviewer that is external to the core team and who has

extensive professional experience in drafting reports for the EC and national authorities is seeked;

Strong collaboration with WP2 needs to be held

7 Problems with (sub)contracting due

to delays in (public) procurement (Likelihood: medium, Impact: high)

WP4 Preparing conditional (public)

procurement and/or framework contracts

8 Difficulty in setting up meetings, mainly due to unavailability of all relevant parties in any

given time (Likelihood: low, Impact: low) WP3,WP4,WP2,WP1

WP team members will make all efforts to adjust other commitments and ensure the presence

9 Losing leadership over outsourced

activities (Likelihood: low, Impact: high) WP4

Communication will be crucial to deliver outputs of the desired quality within the desired timeframe. High-

quality handover of partial tasks and monitoring must be carried out, in order to avoid losing quality and timeliness.

10 A key expert unexpectedly leaves the team

(Likelihood: medium, Impact: medium) WP3,WP4,WP2,WP1

Project managers create possible back-up lists of experts in their within their Competent Authorities/

Affiliated Entities, so that another expert can be promptly involved if needed until a new person is hired.

11 Stakeholder fatigue, lack of incentive with encaging with the consortium or providing feedback. (Likelihood: high, Impact: high)

WP4

The CA and AE will ensure that communication with stakeholders is efficient and respects the

stakeholders time and effort. As such web-based tools will be used to enable engagement at times most

convenient, and incentives such as acknowledgment of contributions will be considered were necessary.

2

Unforeseen Risks

Unforeseen risks

Risk No Description Work Package No(s) Proposed Mitigation Measures

U 1

Implementation of the cross-border Patient Summary microservice on the new platform is part of a broader transition to a microservices platform and is therefore highly dependent on

other microservices that are in the process of being rolled out in the live environment. If significant obstacles arise in the prerequisite work or if changes in national priorities cause a shift in the work schedule, this could hinder meeting the planned deadline for launching

the new Patient Summary microservice. (Likelihood: Medium, Impact: Medium)

WP4

The work on the prerequisite microservices for the Patient Summary implementation is already in progress and,

according to plans, is scheduled to be completed before the deadline for the Patient Summary rollout. In addition,

the same team responsible for implementing the new microservices platform is handling the rollout of the new Patient Summary service. This allows the team, within its capabilities, to manage priorities and the order of tasks to ensure that the project is completed on time.

U 2

National priorities may change and may not align with the goals of the current project. For example if priorities change and other

projects from the Government are deemed more critical than the creation of the new data allergy

standards, then it could lead to delays and cause a poor outcome. (Likelihood:Low, Impact: High)

WP4 MSAE will help steering political

priorities to align with the current project.

3

State of play

State of play Continuous Reporting (Critical Risks screen) - Give the state of play of the risks that were identified in Annex 1 of the Grant Agreement (and new risks that materialised during project implementation) and add new mitigation measures, if needed.

Risk No Period Did you apply risk mitigation measures? Did your risk materialise? Comments

1 1 Yes Yes

Although some tasks began later than initially scheduled due to various factors, project managers proactively adjusted

the timeline and resources to ensure the overall outcome would not be affected.

2 1 Yes No

3 1 Yes No

Financial manager and project managers have monitored the use of resources and made adjustments if needed, meaning the overall budget has not exceeded and all activites so far have been carried out as planned.

4 1 Yes No Coordination and monitoring in WP1 has meant the risk has not realized.

5 1 Yes Yes

Members have been missing for a certain amount of time due to holidays and health

issues, however members have replacements and back-ups for critical tasks who could cover them. In situations where coverage was insufficient or not possible, the team utilized time buffers to ensure that any

delays would not impact overall outcomes.

6 1 Yes No

7 1 Yes No

8 1 Yes No

4

State of play Continuous Reporting (Critical Risks screen) - Give the state of play of the risks that were identified in Annex 1 of the Grant Agreement (and new risks that materialised during project implementation) and add new mitigation measures, if needed.

Risk No Period Did you apply risk mitigation measures? Did your risk materialise? Comments

9 1 Yes No

10 1 Yes Yes

During the reporting period several key experts did leave the team. However suitable replacement experts had been identified and

onboarded. As a result, there was no disruption in the implementation of project activities.

11 1 Yes Yes

There has been some lack of incentive from stakeholders regarding the creation

of new allergy related data exchange standards, however web-based tools (web

questionnaires) have been used and MSAE has helped to communicate the need for the change to stakeholders. Stakeholders have been doubtful of the national impact,

however thorough communication is expected to help mitigate these issues.

U1 1 Yes No

U2 1 Yes No

5

Project: [insert number] — [insert acronym] — [insert call identifier]

EU Grants: Periodic report/Additional prefinancing report/Beneficiary termination report (EU4H): V1.0 – 01.04.2022

TECHNICAL REPORT (PART B)

COVER PAGE

Part B of the Technical Report must be downloaded from the Portal Technical Report (Part B)/Termination Report screen, completed and then assembled and re-uploaded as PDF on that screen.

PROJECT

Project number: [101129187]

Project name: [Estonia towards MyHealth@EU]

Project acronym: [EST-2-MyHealth]

REPORTING PERIOD Please note that you must report on the entire reporting period.

RP number: [1]

Duration: from [01/11/2023] to [31/04/2025]

TABLE OF CONTENTS

TECHNICAL REPORT (PART B) ............................................................................................................................................ 1 COVER PAGE ....................................................................................................................................................................... 1 1. OVERVIEW OF THE PROGRESS .................................................................................................................................... 2

1.1 Summary of work performed and achievements, results and impacts ........................................................................ 2 1.2 Consortium set-up ........................................................................................................................................................ 3 1.3 Project teams, staff and experts .................................................................................................................................. 3 1.4 Consortium management and decision-making ........................................................................................................... 4 1.5 Project management, quality assurance and monitoring and evaluation strategy ....................................................... 4 1.6 Cost effectiveness and financial management ............................................................................................................ 4 1.7 Risk management ........................................................................................................................................................ 4 1.8 Impact .......................................................................................................................................................................... 5 1.9 Communication, dissemination and visibility ................................................................................................................ 5 1.10 Sustainability and continuation .................................................................................................................................. 5 1.11 Follow-up to EU recommendations ............................................................................................................................ 6

2. WORK PLAN, WORK PACKAGES, ACTIVITIES, RESOURCES AND TIMING ............................................................. 7 2.1 Work packages, activities, resources and timing ......................................................................................................... 7

Work Package 1 .......................................................................................................................................................... 7 Work Package 2 .......................................................................................................................................................... 9 Work Package 3 ........................................................................................................................................................ 10 Work Package 4 ........................................................................................................................................................ 11 Subcontracting .......................................................................................................................................................... 13 Timetable .................................................................................................................................................................. 14

3. OTHER ............................................................................................................................................................................ 16 3.1 Ethics ......................................................................................................................................................................... 16 3.2 Security ...................................................................................................................................................................... 16

4. DECLARATIONS ............................................................................................................................................................ 16

Project: [insert number] — [insert acronym] — [insert call identifier]

EU Grants: Periodic report/Additional prefinancing report/Beneficiary termination report (EU4H): V1.0 – 01.04.2022

#@PER-REP-EU4H@# #@PRO-GRE-PG@# [This document is tagged. Do not delete the tags; they are needed for the processing.]

1. OVERVIEW OF THE PROGRESS

1.1 Summary of work performed and achievements, results and impacts

[OPTION 1 by default (all except OG):

Work performed and main achievements Short summary of progress towards the project objectives. Highlight significant activities and achievements. Provide clear and measureable details.

Analyse the outcome of the project (so far) and its (actual and expected) impact (on target groups, change, innovation etc.), including a description of the European dimension and added value. For the Final Report, include the conclusions of the action. Report on objectives not fully achieved or not on schedule.

Do not simply cut and paste the project summary (filled in online on the Summary for Publication screen). Contrary to the summary, this section is for reporting to the EU and will not be published.

The main objective of this project has been ensuring stable routine operations and necessary further developments of the already operational NCPeH.

Main achievements under the proposed action have been so far:

- Bringing Patient Summary service to a new platform – main developments have ended, and procurement finished. However, there is still a need for additional testing and follow-up developments which are currently taking place. When the solution gets deployed live it will mean a more reliable and sustainable service for the citizens and ease the continuous upgrade process for developers. The major upgrade of the Estonian Health Information System is still in progress as there are also other services besides Patient Summary that need to be brought to the new platform together.

- Improving national allergy related data exchange standards - Estonia is currently in the analysis stage and developments are set to begin at the end of 2025. Meetings with stakeholders have been held and will continue. According to the plan the allergy data should be seen on Estonian patients PS-s in 2026, which will help foreign doctors to access important health data of Estonian patients and will ensure the information about allergies is complete.

- Implementing upgrades to the new versions of MyHealth@EU artefacts adopted yearly by the eHMSEG and participating in yearly test events - In the Spring of 2024 Estonia participated in the formal and upgrade test event for OpenNCP Wave 7. As a result, we were able to successfully upgrade our services to the new wave in Autumn of 2024 with all other Member States and got to continue routine operations with ePrescription and Patient Summary services. Through all of 2024 while being in routine operations, Estonia opened services with new country pairs – Greece, Latvia, Lithuania, Czechia, Finland. During Spring 2025 Estonia took part in the next test event and is currently in the process of fixing the issues found during testing and preparing to go live in the following Autumn. There are plans to open services with new joining countries. All of this has meant that Estonia has successfully implemented the yearly upgrades and kept the services running. With that, the usage of the services has grown, Estonian citizens get access to a more reliable healthcare abroad and foreign citizens receive better healthcare in Estonia.

- Translation of the Orphanet rare diseases nomenclature – procurement preparation has taken more time as Estonia had to agree with international coordinating which processes are essential for this specific project. Procurement is set to take place this year and translation process will begin. This will make ORPHAcodes available in Estonian language to Estonian health professionals and when included on the patient summaries of foreign patients’ Estonian health professionals can understand the information in their own language, again making healthcare safer for foreign patients.

Project: [insert number] — [insert acronym] — [insert call identifier]

EU Grants: Periodic report/Additional prefinancing report/Beneficiary termination report (EU4H): V1.0 – 01.04.2022

#§PRO-GRE-PG§# #@CON-SOR-CS@# ]

#§PRO-GRE-PG§# #@CON-SOR-CS@# ]

1.2 Consortium set-up

Participants Report on changes in the consortium composition (including structural, legal or management changes, if any).

See Technical Report (Part A).

Consortium cooperation and division of roles (if applicable) Report on changes in the way the participants work together (Beneficiaries, Affiliated Entities, Associated Partners, etc.).

1.3 Project teams, staff and experts

Project teams and staff Report and explain deviations from Annex 1 of the Grant Agreement regarding the organisation of staff or project teams. Provide CVs of key actors that had to be replaced (if required).

Due to several staffing changes during the reporting period, there have been deviations from the staff originally listed in Annex I of the Grant Agreement. The following table summarises these changes.

Name and function in Annex 1

Organisation New person Reason for change Date of Change

Katre Pruul, project manager

TEHIK Aurelia Mihk Resignation from organisation

October 2023

Andre Lehis, project manager

TEHIK Andry Silla Resignation from organisation

October 2023

Greete Mõttus, project manager

TEHIK Marilin Prants Resignation to another project

September 2024

Jeremin Freed Meister, technical personnel

TEHIK Klaus Martin Vare Resignation to another project

January 2025

Ingrid Hanst, technical personnel

TEHIK Erle Imala Reassigned to another project

March 2024

Hedvig Soone, technical personnel

TEHIK Carmen Mäe Resignation to another project

September 2024

Kerli Linna, technical personnel

TEHIK Carmen Mäe Resignation to another project

September 2024

The change with the biggest impact to the project has perhaps been the resignation of Katre Pruul and with that a new member Aurelia Mihk joining in her place in TEHIK. However, with the help and support from MSAE expert Jaanika Merilo and other TEHIK experts the project has been able to continue as planned and no major deviations from the original project plan have occurred. There have also been

Project: [insert number] — [insert acronym] — [insert call identifier]

EU Grants: Periodic report/Additional prefinancing report/Beneficiary termination report (EU4H): V1.0 – 01.04.2022

changes to other project managers and technical personnel, but these changes have not generated any gaps where certain roles weren’t filled and that has meant the project was able to continue normally.

1.4 Consortium management and decision-making

Consortium management and decision-making (if applicable) Report on important changes in the management or decision-making mechanisms.

Insert text

#§CON-SOR-CS§# #@PRJ-MGT-PM@#

1.5 Project management, quality assurance and monitoring and evaluation strategy

Project management, quality assurance and monitoring and evaluation strategy Report on changes to the overall project management concept, quality assurance and monitoring and evaluation strategy (if any).

Insert text

#§PRJ-MGT-PM§# #@FIN-MGT-FM@#

1.6 Cost effectiveness and financial management

Cost effectiveness and financial management (n/a for Lump Sum Grants)

Inform about significant budget overruns or important changes in the financial management (if any).

In the beginning of the project there were three subcontracts planned. S1.2 included both PS new platform development subcontracting and national allergy data exchange standard creation subcontracting. Since they are both their own projects and taking place at slightly different times, it was decided that there is a need for two separate subcontracts and therefore the budget between these projects was divided as well.

That meant that procurement for PS developments started with a budget of 110 000€. However, as the scope grew, this budget was not enough, and it was decided that some remaining important developments can be financed under S1.1 (developments for cross-border services to ensure their availability) and some of it under our national budget. It did not seem reasonable to cut the budget for allergy as it is known to be a bigger project which needs all its allocated budget. It is foreseen that not all S1.1 will be used strictly for S1.1. Additionally, the subcontracting partners for both S1.1 and S1.2 were the same, which made it possible to continue the work right away, only under a different contract. Otherwise, a need for a new subcontract would’ve risen and that would also bring uncertainty about the new contract partner and might delay the project.

As the Patient Summary platform developments are still ongoing, then it is not possible to conclude how big the exceeding amount will be yet. Under S1.1 there was 10 000€ allocated to platform developments, out of which 9447.03€ have been used.

#§FIN-MGT-FM§# #@RSK-MGT-RM@#

1.7 Risk management

Critical risks and risk management strategy Report on the state of play concerning the risks and risk mitigation measures (if any).

Project: [insert number] — [insert acronym] — [insert call identifier]

EU Grants: Periodic report/Additional prefinancing report/Beneficiary termination report (EU4H): V1.0 – 01.04.2022

See Technical Report (Part A).

#§RSK-MGT-RM§# #@IMP-ACT-IA@#

1.8 Impact

Impact Report on changes in your impact analysis/strategy (if any) and the effects on the project/need for adaptations.

Insert text

#§IMP-ACT-IA§# #@COM-DIS-VIS-CDV@#

1.9 Communication, dissemination and visibility

Communication, dissemination and visibility of funding Report on the communication and dissemination activities undertaken (to whom, which format, how many, etc.). Describe how the visibility of EU funding was ensured. If you described your project on your website(s) and/or social media accounts, please provide the links.

Most of the communication for operational cross-border services has been previously performed and Estonia has mainly continued to raise awareness of the services. There are also many activities planned regarding the allergy project specifically, as this will have the biggest impact nationally on our health professionals. For Estonian citizens allergy data to be present on their patient summaries, the health professionals must be informed about the new standards and how to use them.

TEHIK website already has a dedicated page about cross-border data exchange for the whole public. Information about the current project and funding was added to the page and as we’re reaching the important milestones the page is expected to be updated - https://www.tehik.ee/piiriulene-andmevahetus.

TEHIK has also created a separate page for the allergy data exchange project to the whole public and end-user organizations - https://www.tehik.ee/allergiaandmed.

TEHIK has recently opened a new web page Teabekeskus, all information will be transferred to this page as well, available to the whole public and relevant end-user organizations - https://teabekeskus.tehik.ee/et/teenused/tis-teenused/piiriulene-terviseandmete-andmevahetus. A more specific page for EST-2-MyHealth project will be added by TEHIK.

For Allergy data exchange standard several dissemination meetings have been held with medics from different fields: family doctors, allergists, nurses, emergency doctors etc.

Regarding cross-border services in general, meetings with family doctors and hospital developers were held by TEHIK to raise awareness of the Patient Summary service. There were two meetings where the service was introduced.

TEHIK has sent out several press releases when opening services with new joining countries. There is a mailing list for pharmacies and important information regarding the identification of patients and important information has been shared.

Visibility of EU funding has been ensured by adding a funded by the European Union emblem and specifying the action is co-funded.

See also Technical Report (Part A).

#§COM-DIS-VIS-CDV§# #@SUS-CON-SC@#

1.10 Sustainability and continuation

Sustainability, long-term impact and continuation Report on changes in your sustainability analysis/strategy (if any). For the Final Report, describe the follow-up of the project after the end of the EU grant. How will the results be used or further developed. Describe the strategy to ensure sustainability of results and long-term impact. Comment on possible synergies/complementarities with other (EU funded) activities (if any).

Project: [insert number] — [insert acronym] — [insert call identifier]

EU Grants: Periodic report/Additional prefinancing report/Beneficiary termination report (EU4H): V1.0 – 01.04.2022

Insert text

#§SUS-CON-SC§# #@FOL-UP-FU@#

1.11 Follow-up to EU recommendations

Follow-up to EU recommendations Highlight corrective actions taken as a result of EU monitoring activities (including follow-up to EU project reviews, if any). List each recommendation/comment and explain how they have been followed up.

Insert text

#§FOL-UP-FU§#

Project: [insert number] — [insert acronym] — [insert call identifier]

EU Grants: Periodic report/Additional prefinancing report/Beneficiary termination report (EU4H): V1.0 – 01.04.2022

#@WRK-PLA-WP@#

2. WORK PLAN, WORK PACKAGES, ACTIVITIES, RESOURCES AND TIMING

2.1 Work packages, activities, resources and timing

WORK PACKAGES

Work Package 1

Work Package 1: [Management and coordination]

Activities Report on the implementation status of the activities that were to be implemented during the reporting period and explain deviations from Annex 1 of the Grant Agreement. In case an activity was not implemented or a deliverable not produced, please explain why.

Task No (continuous

numbering linked to WP)

Task Name Implemented? (Yes/No/Partially)

Justification (explain what was done and by whom; explain what was not done and why not;

indicate how you intend to handle the situation and new timing; indicate if it was a one- off issue or how you intend to avoid similar issues in the future)

T1.1 Participation in the European MyHealth@EU governance framework and activities

Yes Aurelia Mihk has been an active member of the eHMSEG, followed the annual activities and has participated in the eHMSEG regular meetings.

In addition, she has participated in the following work groups:

• ePrescription Task Force • Patient Summary Task Force • KPI Task Force • Service Desk Task Force

Jaanika Merilo has been an active member of the eHN and taken part of the regular meetings and activites.

T1.2 Consortium Operating Procedures Definition

Yes Project has a designated Confluence space maintained by TEHIK, where the project plan has been published and all relevant information about the project can be found. All team members have access to the space and can modify the page as needed.

Project: [insert number] — [insert acronym] — [insert call identifier]

EU Grants: Periodic report/Additional prefinancing report/Beneficiary termination report (EU4H): V1.0 – 01.04.2022

T1.3 Coordination of the project management

Yes Regular meetings have been held between TEHIK and MSAE to monitor the progress of the project.

Deliverables and reports have been put together by TEHIK and MSAE project managers.

T1.4 Consortium meeting Yes Kick off meeting was carried out by TEHIK and MSAE back in November 2023. The timeline of the developments was agreed upon by participants and the main starting point was agreed to be the first of January 2024.

Regular meetings did not start before the Autumn of 2024, as this was when the developments and sub-projects were set to begin, they are led by Aurelia Mihk. The only exception were regular cross-border developments which were led by Aurelia Mihk, weekly meetings have taken place since the beginning of the project. MSAE and TEHIK project managers did meet before the official meetings in 2024 began and kept track of the overall progress.

T1.5 Legal management Yes TEHIK and MSAE legal teams are aware of the project and no legal issues have been identified so far.

Other issues Mention and explain unexpected events and adjustments that had to be made. Explain impact on other tasks, available resources and planning/timing.

Insert text

Milestones and deliverables (outputs/outcomes)

See Technical Report (Part A).

Budget implementation — Use of resources (deviations) (n/a for Lump Sum Grants) (n/a for Additional Prefinancing Report) Explain deviations from the budget planning (i.e. differences between actual and planned use of resources, especially for personnel). Include explanations on transfers of cost categories in the estimated budget (if applicable) Don’t forget to attach the detailed cost reporting table (if any).

Insert text

Project: [insert number] — [insert acronym] — [insert call identifier]

EU Grants: Periodic report/Additional prefinancing report/Beneficiary termination report (EU4H): V1.0 – 01.04.2022

Other issues Insert text

Work Package 2

Work Package 2: [Dissemination, training and support]

Activities Report on the implementation status of the activities that were to be implemented during the reporting period and explain deviations from Annex 1 of the Grant Agreement. In case an activity was not implemented or a deliverable not produced, please explain why.

Task No (continuous

numbering linked to WP)

Task Name Implemented? (Yes/No/Partially)

Justification (explain what was done and by whom; explain what was not done and why not;

indicate how you intend to handle the situation and new timing; indicate if it was a one- off issue or how you intend to avoid similar issues in the future)

T2.1 Communication and dissemination Communication strategy and its execution with reports

Yes Dedicated Confluence page has been created by TEHIK and Communication Strategy Plan was delivered to EU on time.

Communication, Dissemination and Training plan was put together by TEHIK and MSAE.

T2.2 Health professional dissemination and education

Partially Health care professionals have been continuously informed about the cross- border services (e.g. when opening services with new countries) and press releases have been sent from TEHIK according to the communication plan.

Presentations have been made by TEHIK to Health Professionals to raise awareness about Patient Summary.

For Allergy data exchange standard several dissemination meetings have been held with medics from different fields: family doctors, allergists, nurses, emergency doctors etc, by TEHIK.

T2.3 Citizen dissemination and motivation

Yes TEHIK web page has been updated by TEHIK with relevant information about the project and new services – project web page has been kept up to date.

Other issues Insert text

Project: [insert number] — [insert acronym] — [insert call identifier]

EU Grants: Periodic report/Additional prefinancing report/Beneficiary termination report (EU4H): V1.0 – 01.04.2022

Mention and explain unexpected events and adjustments that had to be made. Explain impact on other tasks, available resources and planning/timing.

Milestones and deliverables (outputs/outcomes)

See Technical Report (Part A).

Budget implementation — Use of resources (deviations) (n/a for Lump Sum Grants) (n/a for Additional Prefinancing Report) Explain deviations from the budget planning (i.e. differences between actual and planned use of resources, especially for personnel). Include explanations on transfers of cost categories in the estimated budget (if applicable) Don’t forget to attach the detailed cost reporting table (if any).

Insert text

Other issues Insert text

Work Package 3

Work Package 3: [Evaluation and sustainability]

Activities Report on the implementation status of the activities that were to be implemented during the reporting period and explain deviations from Annex 1 of the Grant Agreement. In case an activity was not implemented or a deliverable not produced, please explain why.

Task No (continuous

numbering linked to WP)

Task Name Implemented? (Yes/No/Partially)

Justification (explain what was done and by whom; explain what was not done and why not;

indicate how you intend to handle the situation and new timing; indicate if it was a one- off issue or how you intend to avoid similar issues in the future)

Project: [insert number] — [insert acronym] — [insert call identifier]

EU Grants: Periodic report/Additional prefinancing report/Beneficiary termination report (EU4H): V1.0 – 01.04.2022

T3.1 Evaluation and sustainability plan

Yes Evaluation and sustainability plan was composed by MSAE and TEHIK.

T3.2 Mid-term evaluation report

No To be implemented in the next reporting period.

T3.3 Final evaluation report

No To be implemented in the next reporting period.

Other issues Mention and explain unexpected events and adjustments that had to be made. Explain impact on other tasks, available resources and planning/timing.

Insert text

Milestones and deliverables (outputs/outcomes)

See Technical Report (Part A).

Budget implementation — Use of resources (deviations) (n/a for Lump Sum Grants) (n/a for Additional Prefinancing Report) Explain deviations from the budget planning (i.e. differences between actual and planned use of resources, especially for personnel). Include explanations on transfers of cost categories in the estimated budget (if applicable) Don’t forget to attach the detailed cost reporting table (if any).

Insert text

Other issues Insert text

Work Package 4

Project: [insert number] — [insert acronym] — [insert call identifier]

EU Grants: Periodic report/Additional prefinancing report/Beneficiary termination report (EU4H): V1.0 – 01.04.2022

Work Package 4: [Maintenance and development]

Activities Report on the implementation status of the activities that were to be implemented during the reporting period and explain deviations from Annex 1 of the Grant Agreement. In case an activity was not implemented or a deliverable not produced, please explain why.

Task No (continuous

numbering linked to WP)

Task Name Implemented? (Yes/No/Partially)

Justification (explain what was done and by whom; explain what was not done and why not;

indicate how you intend to handle the situation and new timing; indicate if it was a one- off issue or how you intend to avoid similar issues in the future)

T4.1 Implement upgrades to the new versions of MyHealth@EU artefacts adopted yearly by the eHMSEG and participate

in Annual Upgrade Pre- Production Testing

Yes Estonia took part of the annual Upgrade Pre-Production Testing in Spring 2024 and Spring 2025; test event participation was led by TEHIK and Estonia received the eHMSEG decision to continue routine operations in 2024.

T4.2 Data availability, alignment with eHN guidelines and other service improvements

Partially TEHIK and MSAE started a project to improve data availability of the allergy section on Patient Summary, project is led by Marilin Prants. Stakeholder interest has not been as high as expected and in addition, this task has taken more time due to high workload of the staff members. However, team members have considered that there is a sufficient time buffer, allowing project managers to plan accordingly so the outcome can still be achieved.

The task to bring Patient Summary service to a microservice was led by Andry Silla and while the procurement is finished, there are still tasks that will continue. Additional need for developments came out during testing and to go live with the new platform, there is a need to wait for dependant services to be ready, so everything would work together seamlessly.

TEHIK has been in contact with INSERM to understand the rules of translating the ORPHACode nomenclature. It took more timeas expected and the official translation is yet to start, However TEHIK is currently preparing for the procurement, and the translation is set to begin in the second part of 2025.

Project: [insert number] — [insert acronym] — [insert call identifier]

EU Grants: Periodic report/Additional prefinancing report/Beneficiary termination report (EU4H): V1.0 – 01.04.2022

T4.3 Planning and reporting on service operation and maintenance

Yes Service operation and maintenance report was put together by TEHIK and MSAE.

Other issues Mention and explain unexpected events and adjustments that had to be made. Explain impact on other tasks, available resources and planning/timing.

Insert text

Milestones and deliverables (outputs/outcomes)

See Technical Report (Part A).

Budget implementation — Use of resources (deviations) (n/a for Lump Sum Grants) (n/a for Additional Prefinancing Report) Explain deviations from the budget planning (i.e. differences between actual and planned use of resources, especially for personnel). Include explanations on transfers of cost categories in the estimated budget (if applicable) Don’t forget to attach the detailed cost reporting table (if any).

Insert text

Other issues Insert text

Subcontracting

Subcontracting (new subcontracts) (n/a for Lump Sum Grants) (n/a for Additional Prefinancing Report) Report on new subcontracts. Explain the specific circumstances that caused the need for a subcontract Include only subcontracts that are best-value-for-money and for which there is no conflict of interest. Keep in mind that subcontracting is not possible for key coordinator tasks and may normally not cover a major part of the action.

Subcontract number

Subcontract name Description Costs (EUR)

Justification (why did subcontracting

become necessary?)

Best-value-for- money

Project: [insert number] — [insert acronym] — [insert call identifier]

EU Grants: Periodic report/Additional prefinancing report/Beneficiary termination report (EU4H): V1.0 – 01.04.2022

(continuous numbering linked to

WP)

(subcontracted action tasks)

(including task number and BEN/AE to which it is linked)

(how did you ensure it?)

S1.5

S1.6

…

S2.5

S2.6

…

Other issues If subcontracting for the project rises above 30% of the total eligible costs during the project implementation, give specific reasons. Mention and explain other issues, if needed.

Insert text

Timetable

Timetable (projects of more than 2 years) Report on deviations from Annex 1 of the Grant Agreement. Fill in the planned implementation in beige and the deviations in red. Adapt and repeat lines/columns as necessary.

Starting date: 01.11.2023

ACTIVITY YEAR 1 YEAR 2 YEAR 3 YEAR 4 YEAR 5 YEAR 6

Q 1

Q 2

Q 3

Q 4

Q 1

Q 2

Q 3

Q 4

Q 1

Q 2

Q 3

Q 4

Q 1

Q 2

Q 3

Q 4

Q 1

Q 2

Q 3

Q 4

Q 1

Q 2

Q 3

Q 4

Project: [insert number] — [insert acronym] — [insert call identifier]

EU Grants: Periodic report/Additional prefinancing report/Beneficiary termination report (EU4H): V1.0 – 01.04.2022

Task 2.1 Health professional dissemination and education

#§WRK-PLA-WP§#

Project: [insert number] — [insert acronym] — [insert call identifier]

EU Grants: Periodic report/Additional prefinancing report/Beneficiary termination report (EU4H): V1.0 – 01.04.2022

#@ETH-ICS-EI@#

3. OTHER

3.1 Ethics

Ethics

If your Application Form contains a section on ethics, report on any changes to ethics issues identified in Annex 1 of the Grant Agreement (if any).

Insert text

#§ETH-ICS-EI§# #@SEC-URI-SU@#

3.2 Security

Security

If your Application Form contains a section on security, report on any changes to security issues identified in Annex 1 of the Grant Agreement (if any).

Insert text

#§SEC-URI-SU§# #@DEC-LAR-DL@#

4. DECLARATIONS

[OPTION 1 by default (all except OG):

Double funding

Information concerning other EU grants for this project

Please note that there is a strict prohibition of double funding from the EU budget (except under EU Synergies actions).

YES/NO

We confirm that to our best knowledge neither the project as a whole nor any parts of it benefit/have benefitted from any other EU grant (including EU funding managed by authorities in EU Member States or other funding bodies (e.g. EU Regional Funds, EU Agricultural Funds, tc). If NO, explain and provide details

Yes

We confirm that to our best knowledge neither the project as a whole nor any parts of it are (nor will be) submitted for any other EU grant (including EU funding managed by authorities in EU Member States or other funding bodies (e.g. EU Regional Funds, EU Agricultural Funds, etc). If NO, explain and provide details.

Yes

#§DEC-LAR-DL§# ]

HISTORY OF CHANGES

VERSION PUBLICATION DATE CHANGE

1.0 01.04.2021 Initial version (new MFF). 2.0 02.06.2025 Aurelia Mihk – draft version

Project: [insert number] — [insert acronym] — [insert call identifier]

EU Grants: Periodic report/Additional prefinancing report/Beneficiary termination report (EU4H): V1.0 – 01.04.2022

2.2 16.06.2025 Aurelia Mihk - integrated changes according to comments made by team members. P1.9 added information about allergy communication, linked relevant web pages.

DISSEMINATION ACTIVITIES Definition: The public disclosure of the results by any appropriate means (other than resulting from protecting or exploiting the results), including by scientific publications in

any medium.

Dissemination activity name What?

Type of dissemination activity

Who? Target audience

(Choose one or more items)

Why? (Max 200 characters) Status

Stakeholder meetings for allergy standard Meetings

Industry, business partners, National authorities, Specific end user communities, Innovators

Develop and validate new national FHIR allergy standards and clinical models with stakeholders. Enable Estonian healthcare providers to efficiently implement and submit allergy data to the ENHIS

Ongoing

Meetings with Health Professionals about PS Meetings Industry, business partners, National authorities, Specific end user communities

Raising knowledge on the Patient Summary service and how to use the service. Delivered

Association’s media channels, mailing lists Other Industry, business partners, National authorities, Specific end user communities

New national FHIR based allergy data exchange standards need written information about the launch. Implementing terminology standards for allergy data needs to be validated with stakeholders.

Ongoing

Policy-makers meetings for allergy standard Meetings National authorities

Engage national authorities to validate new allergy standards for Patient Summary, communicate project milestones, and address risks. Keep them updated on industry agreements.

Ongoing

Dissemination of allergy business analysis Other

Research communities, Industry, business partners, National authorities, Specific end user communities

Digital availability ensures easy access for all stakeholders, boosting awareness and accelerating adoption of business analysis, while keeping specialists informed.

Ongoing

Press release for cross-border services Other Citizens

Raise more knowledge on cross-border services, inform citizens about their rights and share information about new countries who have joined with the service.

Ongoing

1

COMMUNICATION ACTIVITIES

** We would advise to give clear guidance of what we expect. It would be very specific Key performance indicators similar to what is suggested by DG COMM for our corporate communication

https://myintracomm.ec.europa.eu/corp/comm/Evaluation/SiteAssets/Pages/Do-You-Need-Methodological-Guidance/Communication%20Network%20indicators%20.pdf

Communication Activity Name Description Who? Target audience How? Communication

channel Outcome Status

Internal communicaton about allergy standard

For TEHIK colleagues useful information exchange about overall lessons learned, suggestions for others in similar project, next steps.

Specific end user communities EVENT

Knowledge is shared, conclusions are made on the success of the project in comparison to the previous attempted allergy projects

ONGOING

Press releases about allergy standard

Press-releases for national communication about release of new allery data exchange standard and solution.

Citizens PRESS_RELEASE

Public and users are informed about the new allergy data standard and exchange. Citizens can be sure their allergy data in different health systems is up to date and same.

ONGOING

Social media updates about allergy standard

Social media update from TEHIK to inform about release of new allery data exchange standard and solution.

Citizens SOCIAL_MEDIA Citizens can be sure their allergy data in different health systems is up to date and same.

ONGOING

Updating TEHIK websites about allergy standard

Up to date information about the new allergy data exchange standard, the project and deadlines in websites: https://www.tehik.ee/ and https://teabekeskus.tehik.ee/et

Citizens WEBSITE

Public is informed and in TEHIK teabekeskus new allergy standard and related implementation guides location is published

ONGOING

Targeted mailing-lists about allergy standard

Using TEHIK andmekorraldus mailing lists to communicate about release of new allery data exchange standard.

Industry, business partners National authorities Specific end user communities

NEWSLETTER

Allergy information is entered by health specialists in high quality and without errors due to new standard.

ONGOING

Creating a web page for the project

To raise awareness of the project and let everyone interested know about the objectives

Citizens Industry, business partners Civil society

WEBSITE Public and partners are aware of the project DELIVERED

Press releases about cross-border services

Press releases for raising overall awareness of cross border services, especially when opening services with new countries.

Citizens PRESS_RELEASE Growth in the usage of the cross- border services ONGOING

Communication: Communication on projects is a strategically planned process that starts at the outset of the action and continues throughout its entire lifetime, aimed at promoting the action and its results. It requires strategic and targeted measures for communicating about (i) the action and (ii) its results to a multitude of audiences, including the media and the public and possibly engaging in a two-way exchange.

2

FINANCIAL SUPPORT TO THIRD PARTIES

Sub-Calls

Awarded Beneficiaries

Call reference Call budget Budget

awarded

Call publication

date

Call closure

date URL to F&T portal Call status

Number of

received proposal

s

Number of

awarded proposal

s

Total: 0.00 € 0.00 €

Call reference PIC Legal name Organisation

type Country Funding awarded(€) Funding paid(€) Comment

Total: 0.00 € 0.00 €

3

EVENTS AND TRAININGS Events and trainings (including workshops, conferences, etc.)

Event No Participant name

Description Attendees

Name Type Area Location Duration (days) Male Femal

e

Non- binar

y Total

4

3. DELIVERABLES

Deliverable No Deliverable Name

Work Package

No Lead Beneficiary Type Dissemination

Level Due Date New Due Date (if delay)

Delivery Date

(actual) Status Comments

D1.1 Project guide WP1 TEHIK R PU 31 January 2024

31 January 2024 APPROVED

D2.1 Communication and dissemination strategy plan

WP2 TEHIK R PU 31 January 2024

31 January 2024 APPROVED

D2.2

MS Service Dissemination, Education and Training Plan

WP2 TEHIK R PU 28 February 2025

28 February 2025

SUBMITTED

D2.5 Project Website WP2 TEHIK DEC PU 30 November 2023

30 November 2023

PENDING

D3.1 Evaluation and sustainability plan WP3 MSAE R PU 31 March

2024 1 April 2024 APPROVED

D4.1 eHMSEG decision M12 WP4 TEHIK R PU 31 October

2024 30 October 2024 APPROVED

D4.4 Service operation and maintenance plan WP4 TEHIK R PU

30 November 2023

4 December 2023

APPROVED

1